Current behavioral assessments of movement disorders in children

Asakawa, Tetsuya; Sugiyama, Kenji; Nozaki, Takao; Sameshima, Tetsuro; Kobayashi, Susumu; Wang, Liang; Hong, Zhen; Chen, Shujiao; Li, Candong; Ding, Ding; Namba, Hiroki

doi:10.1111/cns.13036

Cited by 8 publications

(8 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At every office visit, serial measurements of weight, body mass index (BMI), height, and vital signs were obtained to further monitor for any side effects. Further, the Abnormal Involuntary Movement Scale (AIMS) was completed at every visit for each patient [ 54 ].…”

Section: Methodsmentioning

confidence: 99%

Risperidone or Aripiprazole Can Resolve Autism Core Signs and Symptoms in Young Children: Case Study

et al. 2021

View full text Add to dashboard Cite

Risperidone and aripiprazole are approved by the USA Food and Drug Administration for the treatment of irritability and aggression in children from the ages of 5 and 6 years, respectively. However, there are no approved medications for the treatment of autism spectrum disorder (ASD) core signs and symptoms. Nevertheless, early intervention is recognized as key to improving long-term outcomes. This retrospective case study included 10 children (mean age, 2 years 10 months) with ASD who presented with persistent irritability and aggression before 4 years of age that was unresponsive to behavioral interventions and sufficiently severe to consider pharmacological intervention with risperidone or aripiprazole combined with standard supportive therapies. Besides ameliorating comorbid behaviors, improvement was observed in ASD core signs and symptoms for all patients, with minimal-to-no symptoms observed in 60% of patients according to the Childhood Autism Rating Scale 2-Standard Test and Clinical Global Impression scales. Excessive weight gain in two patients was the only adverse effect observed that required intervention. This is the first study to suggest that ASD can potentially be treated in very young children (<4 years). Clinical trials are urgently required to validate these findings among this pediatric population.

show abstract

Section: Methodsmentioning

confidence: 99%

Risperidone or Aripiprazole Can Resolve Autism Core Signs and Symptoms in Young Children: Case Study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Standardized videotape counting protocols have been tested for many years to develop a practicable, time‐efficient, objective, reliable, and stable tic rating. Today, the most established video‐based assessment of tic severity is the MRVS 3,22 . Because of several scale shortcomings, we developed and tested a revised version, the MRVS‐R.…”

Section: Discussionmentioning

confidence: 99%

“…Today, the most established videobased assessment of tic severity is the MRVS. 3,22 Because of several scale shortcomings, we developed and tested a revised version, the MRVS-R.…”

Section: Discussionmentioning

confidence: 99%

The Rush Video‐Based Tic Rating Scale‐Revised: A Practice‐Oriented Revision

Riechmann

Jakubovski

Essing

et al. 2023

Movement Disord Clin Pract

View full text Add to dashboard Cite

Background The Modified Rush Video‐Based Tic Rating Scale (MRVS) is the most widely used video‐based scale for assessing tic severity in patients with Tourette syndrome (TS). However, shortcomings of the MRVS, including a lack of clear instructions, a time‐consuming recording procedure, and weak correlations with the gold standard for tic assessment, the Yale Global Tic Severity Scale‐Total Tic Score (YGTSS‐TTS), limits its use in research settings, although video assessments are generally considered objective, reliable, and time‐saving measurements. Objectives We aimed to revise the MRVS (MRVS‐R) to simplify and standardize the assessment procedure and improve the correlation with the YGTSS‐TTS. Methods We used 102 videos of patients with TS or persistent motor tic disorder filmed according to the MRVS. We compared the tic frequency assessed by MRVS with frequencies according to MRVS‐R based on a 5‐min (instead of a 10‐min) video to investigate whether reducing the recording time leads to significant changes. In addition, we adapted the MRVS to the YGTSS and defined new anchor values for motor and phonic tic frequency based on frequency distributions as assessed in our sample. Finally, we compared the MRVS‐R and MRVS regarding psychometric properties and correlation with the YGTSS‐TTS. Results Cutting video recording time in half did not significantly affect assessments of motor and phonic tic frequencies. Psychometric properties were acceptable. Most important, proposed revisions of the MRVS improved correlation with the YGTSS‐TTS. Conclusions The MRVS‐R is a simplified version of the MRVS with comparable psychometric qualities, but higher correlations with the YGTSS‐TTS.

show abstract

“…With regard to tools for the assessment of PD, the UPDRS, as a subjective scale, has been constantly modified to include more content of nonmotor items, along with the H&Y, which cannot perform real-time behavioral assessment synchronously with documentation of these motor fluctuations. More accurate evaluation is desired based on the principles of objectification, multipurpose, and simplification, 1 , 2 , 22) in particular because these tests can perform real-time assessment. In our opinion, the use of innovative technologies, such as wearable sensors and the mobile internet, may enable real-time behavioral measurement.…”

Section: Main Limitations In Current Treatment Modalities and Assessmmentioning

confidence: 99%

Can the Latest Computerized Technologies Revolutionize Conventional Assessment Tools and Therapies for a Neurological Disease? The Example of Parkinson’s Disease

Asakawa

Sugiyama

Nozaki

et al. 2019

Neurol. Med. Chir.(Tokyo)

Self Cite

View full text Add to dashboard Cite

Dramatic breakthroughs in the treatment and assessment of neurological diseases are lacking. We believe that conventional methods have several limitations. Computerized technologies, including virtual reality, augmented reality, and robot assistant systems, are advancing at a rapid pace. In this study, we used Parkinson’s disease (PD) as an example to elucidate how the latest computerized technologies can improve the diagnosis and treatment of neurological diseases. Dopaminergic medication and deep brain stimulation remain the most effective interventions for treating PD. Subjective scales, such as the Unified Parkinson’s Disease Rating Scale and the Hoehn and Yahr stage, are still the most widely used assessments. Wearable sensors, virtual reality, augmented reality, and robot assistant systems are increasingly being used for evaluation of patients with PD. The use of such computerized technologies can result in safe, objective, real-time behavioral assessments. Our experiences and understanding of PD have led us to believe that such technologies can provide real-time assessment, which will revolutionize the traditional assessment and treatment of PD. New technologies are desired that can revolutionize PD treatment and facilitate real-time adjustment of treatment based on motor fluctuations, such as telediagnosis systems and “smart treatment systems.” The use of these technologies will substantially improve both the assessment and the treatment of neurological diseases before next-generation treatments, such as stem cell and genetic therapy, and next-generation assessments, can be clinically practiced, although the current level of artificial intelligence cannot replace the role of clinicians.

show abstract

Current behavioral assessments of movement disorders in children

Cited by 8 publications

References 90 publications

Risperidone or Aripiprazole Can Resolve Autism Core Signs and Symptoms in Young Children: Case Study

Risperidone or Aripiprazole Can Resolve Autism Core Signs and Symptoms in Young Children: Case Study

The Rush Video‐Based Tic Rating Scale‐Revised: A Practice‐Oriented Revision

Can the Latest Computerized Technologies Revolutionize Conventional Assessment Tools and Therapies for a Neurological Disease? The Example of Parkinson’s Disease

Contact Info

Product

Resources

About